Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir in Systemic Lupus Erythematosus
NCT02066311Phase 2Terminated
- Sponsor
- Northwell Health
- Start
- Sep 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelfinavir in systemic lupus erythematosus (SLE), sponsored by Northwell Health. Primary endpoint: Inhibition of Anti-dsDNA Binding at 56 days. Started Sep 2014; status: terminated.
02
Drugs
nelfinavir
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02066311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066311.